Pancreatic Cancer Diagnostic Market To Reach $5.15 Billion By 2033

Pancreatic Cancer Diagnostic Market Growth & Trends

The global pancreatic cancer diagnostic market size is expected to reach USD 5.15 billion by 2033, according to a new report by Grand View Research, Inc. Furthermore, the industry is expected to expand at a CAGR of 6.83% from 2026 to 2033. The introduction of innovative products, coupled with the rising need for early disease diagnosis and increasing research activities to develop advanced diagnostic solutions, is anticipated to drive the global market.

For instance, in August 2021, Immunovia, Inc. received approval from the Massachusetts Department of Public Health to start testing patients for pancreatic cancer, using the IMMray PanCan-d test. It is a laboratory-developed test for the early detection of pancreatic cancer. The market is projected to witness lucrative growth opportunities owing to increased research funding, technological advancements in diagnostic tests, and rising efforts from manufacturers to develop precise testing solutions. For instance, in December 2022, Bluestar Genomics, Inc. announced the initiation of one of the largest clinical trials for the early detection of pancreatic cancer.

In addition, the growing demand for developing novel automated and accurate diagnostic solutions to reduce the disease burden worldwide has gained momentum in recent years. Research related to novel biomarker identification, nanoparticle utilization for pancreatic cancer, and the introduction of artificial intelligence (AI) in diagnosis processes are factors projected to fuel the growth. In addition, the incorporation of AI in imaging pathology and biomarkers tests will boost the adoption of diagnostic tests for detecting pancreatic cancer.

For instance, in April 2022, Fujitsu collaborated with Southern Tohoku General Hospital in Fukushima, Japan to develop AI solutions that detect pancreatic malignancy from CT scans at an early stage. Rising investments by key market players in the production of effective and advanced diagnostic tools and various strategic initiatives undertaken by them are likely to create new avenues for market expansion. For instance, in March 2023, Prestige Biopharma Limited developed a first-in-class diagnostic kit for detecting pancreatic cancer. The test helps diagnose the disease at an early stage to improve treatment outcomes and survival rates globally.

Similarly, a favorable regulatory framework for diagnostic tools is another factor supporting market expansion. For instance, in January 2023, the U.S. FDA granted a breakthrough device designation to the OverC Multi-Cancer Detection Blood Test (MCDBT) for the early diagnosis of various forms of cancers, including lung, liver, esophageal, and pancreatic cancer in adults with average and intermediate risk.

 Request a free sample copy or view report summary: Pancreatic Cancer Diagnostic Market Report

Pancreatic Cancer Diagnostic Market Report Highlights 

• The consumables segment led the market with the largest revenue share of 48.65% in 2025. The rising adoption of consumables in diagnostic procedures, Increased R&D investments, and the growing launch of technologically advanced diagnostic kits and reagents are anticipated to support segment expansion.

• The imaging test segment led the market with the largest revenue share of 57.03% in 2025. The growth of the segment is driven by ongoing technological advancements and their critical role in early detection and disease staging.

• The exocrine segment accounted for the largest market revenue share in 2025. The exocrine segment continues to dominate the pancreatic cancer diagnostics market, accounting for a significant share of revenue due to the high prevalence of exocrine malignancies.

• The hospitals segment led the market with the largest revenue share of 56.06% in 2025, driven by increasing patient inflow, expanding access to advanced diagnostic technologies, and rising focus on personalized medicine.

• North America dominated the global pancreatic cancer diagnostic market with the largest revenue share of 39.54% in 2025.

Pancreatic Cancer Diagnostic Market Segmentation

Grand View Research has segmented the global pancreatic cancer diagnostic market on the basis of product, test type, cancer type, end use, and regions:

Pancreatic Cancer Diagnostic Product Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments

• Consumables

• Services

Pancreatic Cancer Diagnostic Application Outlook (Revenue, USD Million, 2021 - 2033)

• Imaging Test

  • CT Scan

  • MRI

  • Ultrasound

  • PET

  • Others

• Biopsy

• Blood Test

  • Liver Function Tests

  • Tumor Markers

  • Others

• Others

Pancreatic Cancer Diagnostic Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)

• Exocrine

  • Adenocarcinoma

  • Squamous Cell Carcinoma

  • Adenosquamous Carcinoma

  • Colloid Carcinoma

• Endocrine

Pancreatic Cancer Diagnostic End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals

• Clinics

• Laboratories

• Others

Pancreatic Cancer Diagnostic Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

List of Key Players of Pancreatic Cancer Diagnostic Market

• Thermo Fisher Scientific, Inc.

• QIAGEN

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd.

• BD

• Agilent Technologies, Inc.

• Myriad Genetics, Inc

• Koninklijke Philips N.V.

• Abbott

• Hitachi, Ltd

• Danaher

• Prestige Biopharma Ltd

• BioMarker Strategies

• ASURAGEN, INC